Coherus Oncology (CHRS) Expected to Release Quarterly Earnings on Wednesday

Coherus Oncology (NASDAQ:CHRS) is expected to be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Coherus Oncology to post earnings of ($0.1150) per share and revenue of $14.4060 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The business had revenue of $12.31 million for the quarter, compared to analyst estimates of $14.22 million. Coherus Oncology had a negative return on equity of 198.90% and a net margin of 397.30%. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Stock Performance

Shares of NASDAQ:CHRS traded down $0.02 during trading on Wednesday, hitting $1.42. 59,562 shares of the stock traded hands, compared to its average volume of 1,551,090. The company has a quick ratio of 1.52, a current ratio of 1.56 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $1.68. Coherus Oncology has a 52-week low of $0.81 and a 52-week high of $2.62. The company has a market cap of $219.65 million, a price-to-earnings ratio of 0.85 and a beta of 0.97.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Coherus Oncology in the 4th quarter valued at $938,000. Panagora Asset Management Inc. lifted its position in shares of Coherus Oncology by 17.8% in the fourth quarter. Panagora Asset Management Inc. now owns 1,620,271 shares of the biotechnology company’s stock valued at $2,301,000 after acquiring an additional 244,303 shares in the last quarter. UBS Group AG lifted its position in shares of Coherus Oncology by 38.5% in the third quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after acquiring an additional 221,410 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Coherus Oncology by 52,980.1% in the first quarter. Acadian Asset Management LLC now owns 196,927 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 196,556 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in shares of Coherus Oncology by 72.9% during the fourth quarter. Bridgeway Capital Management LLC now owns 441,000 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 186,000 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on CHRS shares. Guggenheim started coverage on shares of Coherus Oncology in a report on Monday, May 11th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings raised shares of Coherus Oncology from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 13th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Coherus Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $8.67.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.